Concert Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Concert Pharmaceuticals Inc (CNCE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Concert Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 8M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-99.6% annualized vs trailing 12 months).
- Peer revenue share: Concert Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CNCE Sales vs. its Competitors, Q3 2022
Concert Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -98.5% for Concert Pharmaceuticals Inc. Concert Pharmaceuticals Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Concert Pharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Concert Pharmaceuticals Inc | - | - | - | Yes |
| Competitors combined (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CNCE Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cadrenal Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Concert Pharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Concert Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Concert Pharmaceuticals Inc | 416.25 | 7.91 |
| Cadrenal Therapeutics Inc | 3.26 | - |
| SUBTOTAL | 419.51 | 7.91 |
Sources: Concert Pharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Concert Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Concert Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Concert Pharmaceuticals Inc | 416 | 73,907 | -1,734,523 |
| Cadrenal Therapeutics Inc | 3 | - | -2,542,911 |
| PEERS TOTAL | 3 | - | -2,542,911 |
Concert Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 2.8x | 4.5x | -1.6x |
| Return on Equity | -165.03 % | industry aggregate | -182.27 % |
| Return on Invested Capital | -48.38 % | -2.95 % (avg) | -45.43 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Concert Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | -99.74 % | 500.00 % | -192.66 % | - | 500.00 % | 312.28 % |
| Operating Margin | 37.15 % | -29,406.32 % | 65.30 % | 153.58 % | -7,336.58 % | -919.35 % | -237.92 % |
| Return on Invested Capital | 9.75 % | -24.08 % | 32.69 % | -51.69 % | -28.80 % | -24.46 % | -31.47 % |
| P/E | 20.9x | - | 5.6x | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Concert Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 182.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-99.6% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Concert Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Concert Pharmaceuticals Inc | 6.72 | 9.02 | - |
| Cadrenal Therapeutics Inc | 3.21 | 3.26 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Concert Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Concert Pharmaceuticals Inc | Q3 2022 | -98.5 % | - |
| Cadrenal Therapeutics Inc | Q2 2026 | - | - |
| PEERS TOTAL | -98.5 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Concert Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Concert Pharmaceuticals Inc | Q3 2022 | - | -3.0 % |
| Cadrenal Therapeutics Inc | Q2 2026 | - | - |
Concert Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Concert Pharmaceuticals Inc | - | - | - |
| Cadrenal Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Concert Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Concert Pharmaceuticals Inc | - | 52.64 |
| Cadrenal Therapeutics Inc | - | - |
| PEERS AVERAGE | - | 53.05 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.